BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial.

BioNTech says drug from OncoC4 partnership shows promise in mid-stage trial

MAINZ, Germany, and ROCKVILLE, Maryland, USA, June 2, 2023 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech”) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies' anti-CTLA-4 antibody candidate, BNT316/ONC-392 (gotistobart), in a patient cohort with metastatic, PD-(L)1-resistant non-small cell lung cancer (“NSCLC”). The preliminary results show encouraging clinical anti-tumor activity for BNT316/ONC-392 as a monotherapy in a hard-to-treat patient population, as well as a manageable safety profile. The data will be presented in a poster discussion session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting by Kai He, M.D., Ph.D., Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA.

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

HF Sinclair Corp

Sanmina-SCI

ACM Research

Peabody Energy

Chimerix

PCTEL

Typically, securities may be less appreciated by the market because they stink, which means several proposals for best undervalued growth stocks for June might not make the cut. At the same time, betting on the same ship as everyone else presents its own risks.

7 Deeply Undervalued Growth Stocks to Buy in June

Germany's BioNTech said it was on track to introduce a COVID-19 shot by the early fall in the northern hemisphere that is adapted to currently dominant virus variants in line with recommendations by the World Health Organization.

BioNTech is proceeding with COVID-shot in line with WHO guidance

Fulgent Genetics

Certain biotechs that hit it big early during the pandemic are now undervalued. BioNTech is preparing for a rapid pace of new drug launches.

2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 Years

BioNTech SE has initiation of a phase 3 study using BNT316 as a monotherapy for PD-1/PD-L1 refractory non-small cell lung cancer patients that is expected to take place in 2023. Updated results from the expansion cohort from phase 1/2 study using BNT316 for the treatment of non-small cell lung cancer patients will be presented at ASCO June 2 - 6 of 2023.

BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market

CompX International

Evolution Petroleum

Photronics

Check Point Software Technologies

Epsilon Energy Ltd

Kulicke & Soffa Industries

For those that want to stay in the market during these ambiguous times, investors should consider safe stocks to buy. Basically, as Wall Street rotates away from risk-on assets, companies exclusively tied to growth and little else run the risk of suffering sharp losses.

7 Safe Stocks to Buy for an Economic Downward Spiral

Since initial coverage, BioNTech stock has lost $6 billion in value. BNTX's first quarter revenues were $5.6 billion less than 2022.

BioNTech: Hold Out For More Data (Rating Downgrade)

BioNTech is facing a weak second quarter of 2023 as demand for Covid vaccines wane throughout the warmer summer months. Analysts at Canaccord have noted the drug maker's “seasonal administration pattern” that favors the fall.

BioNTech braces for weak Q2 as Covid vaccine demand subsides

BioNTech SE (NASDAQ:BNTX ) Q1 2023 Results Conference Call May 8, 2023 8:00 AM ET Company Participants Dr. Victoria Meissner - Vice President of Strategy and Investor Relations Ugur Sahin - Chief Executive Officer and Co-Founder Ozlem Tureci - Chief Medical Officer and Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Daina Graybosch - Securities Chris Shibutani - Goldman Sachs Karen Flynn - Morgan Stanley Yaron Werber - Cowen Bill Maughan - Canaccord Zhiqiang Shu - Berenberg Operator Welcome to the BioNTech First Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations.

BioNTech SE (BNTX) Q1 2023 Earnings Call Transcript

BioNTech handily beat first-quarter profit expectations and delivered better-than-expected sales, leading BNTX stock to jump Monday. The post BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations appeared first on Investor's Business Daily.

BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat Expectations

Covid-19 vaccine maker BioNTech SE has reported better-than-expected earnings, exceeding analyst estimates for the first quarter. Sales of €1.28 billion ($1.4 billion) surpassed the €1.1 billion average estimate, while earnings per share reached €2.05, well above the projected $0.69.

BioNTech reports strong 1Q earnings; expands focus beyond Covid-19 vaccines

BioNTech's first-quarter revenue falls from a year earlier as demand for Covid-19 vaccines wanes but still tops analysts' estimates.

BioNTech Revenue Falls. Why the Stock Is Climbing Anyway.

BioNTEch SE's stock BNTX rose 4.3% in premarket trade Monday, after the German biotech posted far stronger-than-expected first-quarter earnings, even as profit and revenue tumbled on lower demand for its COVID vaccine co-developed with Pfizer Inc. PFE. Mainz-based BioNTEch said it had net profit of 502.2 million euros, or 2.05 a share, for the quarter, down from EUR3.699 billion, or EUR14.24 a share, in the year-earlier period.

BioNTech's stock jumps 4.3% premarket after earnings fall but top estimates

COVID-19 vaccine franchise focused on vaccine adaptation readiness ahead of the fall season and advancing next generation vaccine candidates and combinations BioNTech and partner OncoC4 plan to start a Phase 3 clinical trial evaluating anti-CTLA-4 antibody BNT316 (ONC-392) as monotherapy in NSCLC patients who progress after PD-1/PD-L1 treatment Added new class of precision therapeutics to clinical-stage oncology portfolio, with next-generation Antibody-Drug Conjugate (ADC) candidates Presenting clinical data on antibody candidate BNT316 (ONC-392), ADC candidate BNT323 (DB-1303) and CAR-T candidate BNT211 at the 2023 American Society of Clinical Oncology Annual Meeting Broadened clinical-stage infectious disease vaccine pipeline with the start of a First-in-Human clinical trial for the first mRNA-based Tuberculosis vaccine candidates Reiterates BioNTech COVID-19 vaccine revenue guidance of approximately €5 billion in 2023 First quarter1 revenues of €1.3 billion2, net profit of €0.5 billion and fully diluted earnings per share of €2.05 ($2.203) Conference call and webcast scheduled for May 8, 2023, at 8:00 am EDT (2:00 pm CEST) MAINZ, Germany, May 8, 2023 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) today reported financial results for the three months ended March 31, 2023, and provided an update on its corporate progress. “In the first quarter of 2023, we expanded our toolkit of cutting-edge technologies to new modalities and added a novel immune checkpoint inhibitor candidate targeting CTLA-4 and two investigational antibody-drug conjugates to our arsenal against cancer.

BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

Deswell Industries

Chicago Rivet & Machine

Gravity Co

Vir Biotechnology

Although the Federal Reserve aggressively targeted inflation since last year, consumer prices remain stubbornly high, thus incentivizing the case for the best bargain stocks to buy this month. Let's face it – everybody appreciates a good discount.

The 7 Best Bargain Stocks to Buy for May 2023

Tyson Foods

Warner Bros Discovery Inc

In the first half-hour of Thursday's trading, the Dow Jones industrials were down 0.38%, the S&P 500 traded 0.35% and the Nasdaq 0.31% lower.

Earnings Previews: BioNTech, Tyson Foods, Warner Bros Discovery

Pfizer

The U.S. Food and Drug Administration late Friday authorized Pfizer Inc. PFE and BioNTech SE BNTX COVID-19 bivalent vaccine for immunocompromised children. The shot, which would be a fourth dose in most cases, can be given to children older than 6 months through 4 years of age who have previously received the vaccine's three doses, the FDA said.

FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systems

Top Biotech Stocks For Q2 2023: First Gem Is BioNTech.

Top Biotech Stocks For Q2 2023: First Gem Is BioNTech

MAINZ, Germany , April 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2023 on Monday, May 8th, 2023. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2023.

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

DuPont de Nemours

ArcelorMittal

Nutrien

General Motors

Labcorp Holdings Inc

While the concept of acquiring low-PE ratio blue-chip stocks (that is, industry-leading stalwarts that feature low price-earnings ratios relative to their sectors) appeals on paper, investors need to be cautious. You can't just buy companies based on any one single metric.

7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value

Moderna

To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.

FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations

BioNTech SE BNTX, +1.63% said Monday it has entered a partnership with Shanghai-based Duality Biologics to acclereate the development of antibody-drug conjugates to treat patients with cancer and autoimmune diseases. The agreement covers two ADC assets and involves exclusive license to develop, manufacture and commercialize them globally, excluding Mainland China, Hong Kong and Macau.

BioNTech enters cancer drug partnership with DualityBio

MAINZ, Germany and SHANGHAI, China, April 3, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next generation antibody-drug conjugate (“ADC”) therapeutics to treat patients with cancer and autoimmune diseases, today announced that the companies have entered into exclusive license and collaboration agreements for two ADC assets to develop, manufacture and commercialize the two assets globally, excluding Mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in BioNTech's oncology portfolio with the aim to further support BioNTech's mission of developing highly efficacious therapies for cancer patients at every stage of disease.

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

BioNTech is quite undervalued after you back out its tremendous and growing cash hoard garnered from its COVID vaccine windfall. The company's mRNA technology and other therapies in development could support one of the cheapest long-term buy entries in the biotech/pharma sector.

News for BioNTech SE Stock (BNTX)